BLACK DIAMOND THERAPEUTICS I

BDTXNASDAQ

🏆 #4071 by market capEarnings Nov 4US Equity

$831.22▲ $12.88 (+1.55%)

Simulated price

🔔

Track BDTX

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 1.6%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$105M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Good

No chart data available for BDTX.

Trading Snapshot

Day Range: $821.36 – $845.32
52-Week Range: $1.60 – $4.94
Volume: $2.63B
Avg Volume: $3.10B
Shares Outstanding: 57.3M
Next Earnings: Nov 10, 2026

Fundamentals Snapshot

Annual Revenue: $70M
Last Q Revenue: $18M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.74
Dividend Yield: —
Dilution (1yr): +0.9%

Why Investors Own BDTX

✓High-growth profile — revenue up +38.4% YoY with expanding US Equity exposure.
✓Healthy economics — 48% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BLACK DIAMOND THERAPEUTICS I

BDTX

Financial Trends

Revenue

$70M▲ +0.0% YoY

Operating Income

$20M▼ −125.2% YoY

Free Cash Flow

$30M▼ −147.5% YoY

Shares Outstanding

57.1M▲ +0.9% YoY

Net Cash

$2M▼ −$12M YoY

StockOtter · stockotter.space

About BLACK DIAMOND THERAPEUTICS I

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

🦦